Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

About this update from Aytu Biopharma, Inc.

DENVER, CO / ACCESSWIRE / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its first quarter of fiscal year 2024 for the period ended September 30, 2023 , after the market close on Tuesday, November 14, 2023 . The Company has scheduled a conference call that same day, Tuesday, November 14, 2023 , at 4:30 pm ET , to review the results. Conference Call Information Date and Time : Tuesday, November 14, 2023 , at 4:30 pm ET Call-in Information : Interested parties can access the conference call by dialing (888) 506-0062 or (973) 528-0011 using the participant access code 748565. Webcast Information: The webcast will be accessible live and archived at the following link, https://www.webcaster4.com/Webcast/Page/2142/49357 and on Aytu BioPharma's website, within the Investors section under Events & Presentations, at aytubio.com , for one year. Replay: A teleconference replay of the call will be available until November 28, 2023 at (877) 481-4010 or (919) 882-2331, replay access code 49357. About Aytu BioPharma, Inc. Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Aytu's consumer health segment markets a range of over-the-counter medicines and consumer health products addressing a range of common conditions including diabetes, allergy, hair regrowth, and gastrointestinal conditions. To learn more, please visit aytubio.com . Contacts for Investors: Mark Oki , Chief Financial Officer Aytu BioPharma, Inc. [email protected] Robert Blum or Roger Weiss Lytham Partners [email protected] SOURCE: Aytu BioPharma, Inc. View source version on accesswire.com : https://www.accesswire.com/800372/aytu-biopharma-to-report-first-quarter-fiscal-2024-financial-results-on-november-14-2023

View stock analysis, news, and events for Aytu Biopharma, Inc.